Last updated: July 17, 2026

Application No. 18/484,361

Methods for Producing Fabs and IgG Bispecific Antibodies

Non-Final OA

Filed

Oct 10, 2023

Priority

Dec 22, 2016 — provisional 62/437,740 +2 more

Examiner

BRISTOL, LYNN ANNE

Art Unit

1643

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

The University of North Carolina at Chapel Hill

OA Round

1 (Non-Final)

This examiner grants 64% of cases after interview

— +39.8% interview lift. A telephonic interview to clarify the technical implementation could significantly improve the outcome.

Based on 1148 resolved cases, 2023–2026

Examiner Intelligence

BRISTOL, LYNN ANNE View full profile →

Grants 64% of resolved cases

Career Allowance Rate

729 granted / 1148 resolved

+3.5% vs TC avg

Strong +40% interview lift

Without

With

+39.8%

Interview Lift

resolved cases with interview

Typical timeline

3y 4m

Avg Prosecution

57 currently pending

Career history

1213

Total Applications

across all art units

Statute-Specific Performance

§101

1.1%

-38.9% vs TC avg

§103

15.7%

-24.3% vs TC avg

§102

6.5%

-33.5% vs TC avg

§112

45.4%

+5.4% vs TC avg

Black line = Tech Center average estimate • Based on career data from 1148 resolved cases

Prosecution Timeline

Oct 10, 2023

Application Filed

Jun 12, 2026

Non-Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

17/636,440

Patent 12662536

Bispecific Antibody Targeting CD3 and CD20 and Use Thereof

4y 4m to grant Granted Jun 23, 2026

18/145,254

Patent 12655211

ANTIBODIES TARGETING G-PROTEIN COUPLED RECEPTOR AND METHODS OF USE

3y 5m to grant Granted Jun 16, 2026

18/340,367

Patent 12649789

ANTIBODIES BINDING SIGLEC15 AND USES THEREOF

2y 11m to grant Granted Jun 09, 2026

18/408,414

Patent 12649790

PROTEINS THAT BIND SP17 INCLUDING FULLY-HUMAN ANTI-SP17 ANTIBODIES

2y 5m to grant Granted Jun 09, 2026

17/982,481

Patent 12630651

ANTI-SCLEROSTIN CONSTRUCTS AND USES THEREOF

3y 6m to grant Granted May 19, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2

Expected OA Rounds

64%

Grant Probability

99%

With Interview (+39.8%)

3y 4m (~7m remaining)

Median Time to Grant

Low

PTA Risk

Based on 1148 resolved cases by this examiner. Grant probability derived from career allowance rate.